Perseus-Soros Management has sold its remaining 1.7 million share stake in drug company Adams Respiratory Therapeutics (Nasdaq: ARXT) for around $44 million, according to The New York Post.
Return to search
![]()
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.